摘要
目的 观察复元和中汤联合FOLFOX方案[氟尿嘧啶(Fluorouracil)、亚叶酸(Folinic acid)和奥沙利铂(Oxaliplatin)]治疗晚期胃癌患者的临床疗效及对其胃肠功能与T淋巴细胞亚群的影响。方法 选取2020年6月—2022年6月鹤山市中医院收治的60例晚期胃癌患者为研究对象,按照随机数字表法分为对照组和治疗组,每组各30例。对照组给予常规FOLFOX方案治疗,治疗组采用复元和中汤联合FOLFOX方案治疗,21 d为1个疗程,共治疗4个疗程。观察比较两组患者临床疗效、安全性,治疗前后胃肠功能[血浆D-乳酸、尿液乳果糖/甘露醇(Lactulose/Mannitol, L/M)值]、T淋巴细胞亚群(CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+))水平及肿瘤标志物[血清癌胚抗原(Carcinoembryonicantigen, CEA)、糖类抗原199(Carbohydrate antigen 199,CA199)]水平。结果 治疗后治疗组近期总缓解率50.00%(15/30)明显高于对照组23.33%(7/30),差异有统计学意义(P<0.05)。治疗后两组患者胃肠功能指标D-乳酸水平及尿液L/M值均较治疗前降低,差异有统计学意义(P<0.05);且治疗组血浆D-乳酸水平及尿液L/M值均明显低于对照组,差异有统计学意义(P<0.05)。治疗后两组患者血清CEA、CA19-9水平均低于治疗前,差异有统计学意义(P<0.05);且治疗组血清CEA、CA19-9水平明显低于对照组,差异有统计学意义(P<0.05);治疗后治疗组患者血清CD4^(+)及CD4^(+)/CD8^(+)水平均高于治疗前、CD3^(+)水平低于治疗前,差异有统计学意义(P<0.05);且治疗组患者血清CD3^(+)、CD4^(+)及CD4^(+)/CD8^(+)水平均明显高于对照组,差异有统计学意义(P<0.05)。治疗期间,治疗组患者不良反应发生率16.67%(5/30)明显低于对照组40.00%(12/30),差异有统计学意义(P<0.05)。结论 复元和中汤联合FOLFOX方案对晚期胃癌患者胃肠功能及T淋巴细胞亚群水平具有良好的改善作用,能够降低肿瘤标志物水平,调节免疫功能,提升疗效,减少不良反应的发生。
Objective To investigate the clinical efficacy of Fuyuan Hezhong decoction combined with FOLFOX(Fluorouracil,Folinic acid,and Oxaliplatin)program on gastric cancer patients,as well as the combined treatment's effectson gastrointestinal function and T lymphocyte subpopulation.Methods Sixty gastric cancer patients treated in Heshan Hospital of Chinese Medicine from June 2020 to June 2022 were selected as the study subjects.They were divided into a control group and a treatment group using a random number table,with 30 patients in each group.The control group wastreated with the conventional FOLFOX program,while the study group was additionally given Fuyuan Hezhong decoction.The treatment lasted for four courses,with 21 days in each course.After the treatment,clinical efficacy and security werecompared in each group.The following aspects were also compared before and after treatment:gastrointestinal function[serum D-lactic acid and urine lactulose/mannitol(L/M)value],T lymphocyte subpopulation(CD3^(+),CD4^(+),and CD4^(+)/CD8^(+))levels,and rumor marker[serum Carcinoembryonic antigen(CEA)and Carbohydrate antigen 199(CA199)] levels.Results After treatment,the short-term total remission rate of the treatment group was 50.00%(15/30),significantlyhigher than that of the control group(23.33%,7/30)(P<0.05).The serum D-lactic acid level and urine L/M valuewere significantly decreased in both groups,with both items being significantly lower in the treatment group(P<0.05).The serum CEA and CA199 levels were decreased in both groups,with both levels being significantly lower in the treatmentgroup(P<0.05).Affer treatment,the serum levels of CD4^(+)and the CD4^(+)/CD8^(+)ratio in the treatment group were significantly higher than those before treatment,while the CD3^(+)level was significantly lower than that before treatment(P<0.05).Moreover,the serum levels of CD3^(+),CD4^(+),and the CD4^(+)/CD8^(+)ratio in the treatment group were significantlyhigher than those in the control group(P<0.05).During treatment,the adverse reaction incidence in the treatment groupwas 16.67%(5/30),significantly lower than that in the control group(40.00%,12/30)(P<0.05).Conclusion Thecombination of Fuyuan Hezhong decoction and the FOLFOX program can effectively improve gastrointestinal function and Tlymphocyte subpopulation levels in gastric cancer patients,reduce tumor marker levels and regulate immune function.Theclinical efficacy can be enhanced,while the adverse reaction incidence can be reduced.
作者
曾晓明
曾晓荣
钟斯婷
何传强
刘敏
ZENG Xiao-ming;ZENG Xiao-rong;ZHONG Si-ting;HE Chuan-qiang;LIU Min(Guangzhou University of Chinese Medicine,Guangzhou Guangdong 510405;Department of Traditional Chinese Medicine,Heshan Hospital of Chinese Medicine,Heshan Guangdong 529700;Department of Orthopedics,Dongguan HospitalAffiliated to Guangzhou University of Chinese Medicine,Dongguan Guangdong 523003;Department of Oncology,HeshanHospital of Chinese Medicine,Heshan Guangdong 529700;Famous Traditional Chinese Medicine Studio,Heshan Hospital of Chinese Medicine,Guangdong Heshan 529700;Department of Endocrinology,the First Affiliated Hospital of Guangzhou University of Chinese Medicine,Guangzhou Guangdong 510405)
出处
《世界中西医结合杂志》
2025年第7期1361-1365,共5页
World Journal of Integrated Traditional and Western Medicine
基金
江门市科技计划项目(2022YL11006)。
关键词
复元和中汤
FOLFOX方案
胃癌
胃肠功能
T淋巴细胞亚群
Fuyuan Hezhong Decoction
FOLFOX Program
Gastric Cancer
Gastrointestinal Function
T Lymphocyte Subpopulation
作者简介
通信作者:刘敏,Email:liumery@163.com。
